No Data
No Data
Xiangyu Medical (688626.SH): Has repurchased 1.1375% of the company's shares.
On August 2, Gelonhui reported that Xiangyu Medical (688626.SH) announced that as of July 31, 2024, the company had repurchased a cumulative total of 1,820,000 shares of the company through the Shanghai Stock Exchange trading system using centralized bidding trading, accounting for 1.1375% of the total share capital of 160,000,000 shares of the company. The highest and lowest transaction prices for the repurchase were 52.19 yuan/share and 26.80 yuan/share, respectively. The total amount of funds paid was RMB 76,982,680.40 (excluding transaction fees such as trading commissions and transfer fees).
Shangyu Medical (688626.SH): The second-instance judgment has been fully implemented and has paid 16.8466 million yuan to Henan Wujian.
On July 29, Gelunhui announced that Xiangyu Medical (688626.SH) had completed the second-instance judgment. After a partial amount offset, the company has paid 16.8466 million yuan to Henan Wujian (including the returned deposit and interest) through negotiation. According to the final judgment, the company has fulfilled the normal payment of corresponding engineering fees, returned the related expenses and deposits generated by borrowing materials, and the company has withdrawn the engineering fees according to the first-instance judgment. It is expected that it will not have a significant adverse impact on the company's current and future profits and losses.
Xiangyu Medical (688626.SH): Currently, there is no major change in the company's fundamentals.
Recently, Xiangyu Medical (688626.SH) stated during a reception for institutional investors that due to factors such as the Spring Festival holiday, the first quarter is generally the off-season compared to the whole year, with less income; currently the company's fundamentals have not changed significantly. In recent years, it has been a critical period for the company to seize opportunities, optimize its structure, and enhance its scale. With the gradual establishment of national R&D centers, there may be fluctuations in net income in the short term, but in the long term, it will become an important driving force for the high-quality development of the company.
Xiangyu Medical (688626.SH): In 2024, it will focus on R&D of high-end medical devices for mental and psychological rehabilitation.
On July 17th, Gelunhui reported that when receiving institutional investor research, Xiangyu Medical (688626.SH) stated that the company's own products include rehabilitation assessment equipment, rehabilitation training equipment, rehabilitation therapy equipment, rehabilitation aids, and rehabilitation care equipment. It has formed a rich product structure of more than 20 series and 600 own products. In the field of rehabilitation medical equipment, it has a relatively complete product system. By 2024, the company will focus on high-end rehabilitation equipment research and development such as mental and psychological rehabilitation, brain-computer interface, rehabilitation robots, shock waves, smart OT rehabilitation, and home rehabilitation, and continue to promote and optimize clinical rehabilitation integration solutions.
Returns On Capital Signal Tricky Times Ahead For Xiangyu MedicalLtd (SHSE:688626)
Medical company Xiangyu (688626.SH) has spent 75.3852 million yuan to repurchase 1.10% of its shares.
Shanghai Xiangyu Medical (688626.SH) announced that as of June 30, 2024, the company has passed the Shanghai Stock Exchange...
No Data